Long-Term Efficacy and Duration of MFU-V at Multiple Depths and at 1.5 mm

This study is a prospective, single-center clinical trial designed to evaluate the long-term safety and effectiveness of Ultherapy Prime (MFU-V) for improving lines, wrinkles, and skin laxity of the lower face, submentum, and neck. Ultherapy Prime is an FDA-cleared focused ultrasound device indicated for non-invasive lifting and tightening of the skin under the chin, on the neck, and on the brow, as well as for improving lines and wrinkles of the décolleté. The device delivers precise micro-focused ultrasound energy at controlled depths beneath the skin's surface to stimulate neocollagenesis-the natural production of new collagen that contributes to skin firmness, elasticity, and support.

The objective of this study is to assess clinical outcomes following a single Ultherapy Prime treatment using either a multi-depth protocol or a single-depth protocol at 1.5 mm. The study will enroll 20 adult subjects aged 25 to 65 with moderate to severe laxity or crepiness of the lower face and neck who are appropriate candidates for non-invasive energy-based treatment.

Participants will be randomized to receive Ultherapy Prime at either multiple treatment depths or at the 1.5 mm depth alone. All subjects will undergo standardized 2D and 3D digital photography, clinical assessments, and patient-reported outcome measures over a 12-month follow-up period. Investigator-assessed and patient-reported evaluations-including the Global Aesthetic Improvement Scale (GAIS), cutometer elasticity measurements (if applicable), and satisfaction scales-will be used to assess changes in skin quality, lifting, tightening, and overall aesthetic improvement.

The study includes five visits: a combined Screening/Treatment Visit, and follow-up visits at 1 month, 3 months, 6 months, and 12 months post-treatment. The Screening/Treatment Visit will include informed consent, eligibility confirmation, pregnancy testing if applicable, baseline imaging, and delivery of the assigned Ultherapy Prime treatment. Participants must avoid applying any lotions, moisturizers, or topical products to the treatment area prior to each visit. The treatment area must be free of hair; if shaving is required, participants must shave the day before treatment.

To reduce confounding variables, subjects must refrain from undergoing elective aesthetic procedures involving the lower face, submentum, or neck for the duration of the 12-month study. Safety will be monitored throughout the trial through documentation of adverse events, subject-reported symptoms, and clinical examinations. Because Ultherapy Prime is already FDA-cleared for the anatomical regions being treated, and because treatment involves a single non-invasive procedure, the study is considered minimal risk.

This research will contribute to a deeper understanding of the duration and extent of clinical benefits associated with Ultherapy Prime, as well as whether multi-depth treatment results in greater or longer-lasting improvement compared to treatment at a single depth.

Inclusion criteria

• Male or female subjects between 25 and 65 years of age at the time of screening.

Presence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and/or neck that is appropriate for improvement with non-invasive MFU-V treatment.

Skin condition not advanced enough to require surgical correction.

Willingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study.

Ability and willingness to comply with all study visits, procedures, and follow-up requirements.

Sufficient English language proficiency to understand study instructions and complete questionnaires.

For participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study.

Ability to provide written informed consent.

Exclusion criteria

• Male or female subjects between 25 and 65 years of age at the time of screening.

Presence of moderate to severe laxity, fine lines, or crepiness of the lower face, submentum, and/or neck that is appropriate for improvement with non-invasive MFU-V treatment.

Skin condition not advanced enough to require surgical correction.

Willingness to refrain from elective aesthetic procedures involving the face, submentum, or neck for the entire 12-month duration of the study.

Ability and willingness to comply with all study visits, procedures, and follow-up requirements.

Sufficient English language proficiency to understand study instructions and complete questionnaires.

For participants of childbearing potential: negative urine pregnancy test on the day of treatment and willingness to use adequate contraception during the study.

Ability to provide written informed consent.

Exclusion criteria

Active systemic or local skin disease (e.g., eczema, psoriasis, dermatitis, infection) that may affect wound healing or the evaluation of results.

Scarring, tattoos, or significant pigmentary alterations in the planned treatment areas.

Metallic implants or other implanted electronic devices (e.g., pacemakers) in or near the treatment area.

Open wounds, lesions, active herpes simplex, or active cystic/severe inflammatory acne in the treatment area.

Use of isotretinoin or other oral retinoids within the past 12 months or planned use during the study.

Microdermabrasion or medical-grade glycolic acid treatments to the treatment area within 2 weeks prior to participation.

Deep dermal scarring, thick sebaceous skin, or severe solar elastosis in the treatment area that may interfere with treatment or evaluation.

Intention to gain or lose ≥ 2 BMI units during the 12-month study period.

Known allergy or hypersensitivity to any component of the device or ultrasound coupling gel.

History of chronic drug or alcohol abuse or opioid dependence.

Recent aesthetic procedures to the lower face, submentum, or neck that may confound study outcomes (e.g., fillers, neurotoxins, lasers, threads, RF, ultrasound) within the protocol-specified washout period.

Participation in another clinical study involving an investigational device or drug within 30 days prior to treatment.

Pregnancy, breastfeeding, or plans to become pregnant during the study.

Any condition that, in the opinion of the investigator, would increase risk or interfere with study participation or data interpretation.